Managing metastatic bone disease: Three case studies

Seminars in Oncology

Volumn 31, Issue SUPPL. 10, 2004, Pages 83-86

  Coleman, Robert ^a   Heidenreich, Axel ^b   Bell, Richard ^c  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

^c GEELONG HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; IBANDRONIC ACID; LETROZOLE; LEXIDRONAM SAMARIUM SM 153; METHOTREXATE; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PARACETAMOL; PREDNISONE; STRONTIUM 89; TAMOXIFEN; ZOLEDRONIC ACID;

AGED; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER PAIN; CASE REPORT; CLINICAL TRIAL; CONFERENCE PAPER; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; LONG TERM CARE; MALE; NEPHROTOXICITY; PATIENT CARE; PRIORITY JOURNAL; SIDE EFFECT; TOXICITY;

ADMINISTRATION, ORAL; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; NEOPLASMS, SECOND PRIMARY; PALLIATIVE CARE; PROSTATIC NEOPLASMS;

EID: 5644295429     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.07.028     Document Type: Conference Paper

References (20)

1. R.E. Coleman Metastatic bone disease clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 2001 165 176
2. R.E. Coleman, O.P. Purohit, C. Black Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease Ann Oncol 10 1999 311 316
3. B.I. Carlin, G.L. Andriole The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma Cancer 88 suppl 12 2000 2989 2994
4. S.N. Pentyala, J. Lee, K. Hsieh Prostate cancer a comprehensive review Med Oncol 17 2000 85 105
5. A. Berrutti, L. Dogliotti, R. Bitossi Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease predictive role of bone resorption and formation markers evaluated at baseline J Urol 164 2000 1248 1253
6. N. Janjan Bone metastases approaches to management Semin Oncol 28 suppl 11 2001 28 34
7. B. Rasmusson, I. Vejborg, A.B. Jensen Irradiation of bone metastases in breast cancer patients a randomized study with 1 year follow-up Radiother Oncol 34 1995 179 184
8. G.N. Hortobagyi Novel approaches to the management of bone metastases Semin Oncol 30 suppl 16 2003 161 166
9. N.A. Janjan Radiation of bone metastases conventional techniques and the role of systemic radiopharmaceuticals Cancer 80 suppl 8 1997 1628 1645
10. V.J. Lewington, A.J. McEwan, D.M. Ackery A prospective, randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to the bone Eur J Cancer 27 1991 954 958
11. I. Resche, J.F. Chatal, A. Pecking A dose-controlled study of 153Sm-Ethylenediaminetetramethylenephosphate (EDTMP) in the treatment of patients with painful bone metastases Eur J Cancer 33 1997 1583 1591
12. R.G. Robinson, D.F. Preston, K.G. Baxter Clinical experience with strontium-89 in prostatic and breast cancer patients Semin Oncol 20 suppl 2 1993 44 48
13. A.N. Serafini, S.J. Houston, I. Resche Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam a double-blind placebo-controlled clinical trial J Clin Oncol 16 1998 1574 1581
14. I.F. Tannock, D. Osoba, M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer a Canadian randomized trial with palliative endpoints J Clin Oncol 14 1996 1756 1764
15. L.S. Rosen, D. Gordon, M. Kaminski Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma a phase III, double blind, comparative trial Cancer J 7 2001 377 387
16. N. Pavlakis, M. Stockler Bisphosphonates for breast cancer Cochrane Database Syst Rev 1 2002 CD003474
17. F. Saad, D.M. Gleason, R. Murray A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
18. J.-J. Body, I.J. Diel, M.R. Lichinitser Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 14 2003 1399 1405
19. J.J. Body, I.J. Diel, M. Lichinitzer Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease results from two randomised, placebo-controlled phase III studies Br J Cancer 90 2004 1133 1137
20. A. Heidenreich, C. Ohlmann, P. Olbert High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcemia due to metastatic urologic cancer [abstract 897] Eur J Cancer 1 suppl 5 2003 S270